Directa Plus PLC (LON:DCTA) announced it has received another positive test result confirming that its graphene nanoplatelets are not absorbed through human skin.
The graphene producer said this was the eighth in vitro test to show that there is no absorption potential for the Pure G+ powder.
READ: Directa Plus signs agreements with NexTech Batteries for lithium sulphur batteries
The study was carried out by an independent third party and followed international standards, using human skin reconstructed in the lab.
Pure G+ was applied on the tissue surface for six and 24 hours and at the end of the experimental time, it was calculated how much Pure G+ graphene had penetrated through the skin.
The AIM-listed firm said successful results from in vitro tests of its hypoallergenic, non-toxic products are vital for their use in textile markets, where customers have to be certain of the safety of the apparel they produce and market.
"Our suite of successful in vitro tests proves to customers in the textile industry that they can safely adopt our products to create exciting new garments enhanced by our graphene products,” chief executive Giulio Cesareo commented in a release.
“We will continue to ensure that our products are tested to the highest possible standards before releasing them to our target markets, in keeping with our core values."
Shares added 4% to 123.2p on Tuesday at the opening bell.